Gastrointestinal Cancer

Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.

A new drug application has been submitted for MM-398 in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer following prior treatment with a gemcitabine-based therapy.

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

To gain insight into the diagnosis and treatment of HCC, OncLive interviewed Laura Dawson, MD, FRCPC, a professor in the Department of Radiation Oncology at the University of Toronto.

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, discusses increasing cause of hepatocellular carcinoma (HCC) and unmet needs related to the disease.

Alok A. Khorana, MD, specializes in predictive factors in gastrointestinal oncology and in cancer-associated thrombosis at the Cleveland Clinic. He provided insight on gastric cancer research in an interview with OncLive.

Maurie Markman, MD, offers examples of clinical trials where the interpretation of study results is worthy of considerable additional discussion or where justification for the actual conduct of the study can be called into question.